Background: The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods: One month after they had undergone implantation of a biodegradable-polymer sirolimus-eluting coronary stent, we randomly assigned patients at high bleeding risk to discontinue dual antiplatelet therapy. Importance: Despite antirestenotic efficacy of coronary drug-eluting stents (DES) compared with bare metal stents (BMS), the relative risk of stent thrombosis and adverse cardiovascular events is unclear. Although dual antiplatelet therapy (DAPT) beyond 1 year provides ischemic event protection after DES, ischemic event risk is perceived to be less after BMS, and the appropriate duration of. Cessation of dual antiplatelet therapy (DAPT) during this period, particularly in cases of patients undergoing surgery, is associated with an unacceptable rate of stent thrombosis, which is often catastrophic. Thus, a minimum duration of DAPT for 1 month is generally recommended in stable ischemic heart disease (SIHD) patients treated with a BMS. Dual antiplatelet therapy for patients with indication for oral anticoagulation 238 7.1 Risk stratification and strategies to improve outcome after percutaneous coronary intervention 238 7.2 Duration of triple therapy 239 7.3 Cessation of all antiplatelet agents 242 7.4 Type of anticoagulants 242 7.5 Type of stent 242. 8. Elective non-cardiac surgery in patients on dual antiplatelet therapy. DAPT (Dual Antiplatelet Therapy) trial. 5. DES LATE (Optimal Duration of Clopidogrel Therapy With DES to Reduce Late Coronary Arterial Thrombotic Event) trial. 4. OPTIDUAL (Optimal Dual Antiplatelet Therapy) trial. 3. The summary of these trials can be seen in Table 1. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014; 384:1577–1585. doi: 10.1016/S0140-6736(14)60612-7 Crossref Medline Google Scholar; 19. Helft G, Steg PG, Le Feuvre C, Georges JL, Carrie D, Dreyfus X, Furber A, Leclercq F, Eltchaninoff H, Falquier JF, et al.; Optimal Dual Antiplatelet Therapy Trial. Antiplatelet agents are a class of drugs that inhibit the platelets from clumping together and forming blood clots. Many heart attack and stroke patients — and people seeking to avoid these events — are treated with two types of antiplatelet agents to prevent blood clotting. This is called dual antiplatelet therapy (DAPT). QUICK TAKE Dual Antiplatelet Therapy Post-PCI in Patients at High Bleeding Risk 02:07. Randomized trials have established the superiority of drug-eluting stents over bare-metal stents in patients. ESC Clinical Practice Guidelines aim to present all the relevant evidence to help physicians weigh the benefits and risks of a particular diagnostic or therapeutic procedure on Dual Antiplatelet Therapy (DAPT). They should be essential in everyday clinical decision making. The DAPT Score gives clinicians an opportunity to see how patients with particular characteristics fared when randomized to either 30 months or 12 months of dual antiplatelet therapy after receiving a stent. The data are based on the largest ever randomized blinded trial of antiplatelet therapy that we led at the Baim Institute for Clinical Research (formerly Harvard Clinical Research.